普利製藥(300630.SZ):注射用鹽酸萬古黴素獲哥斯達黎加衞生部上市許可
格隆匯2月16日丨普利製藥(300630.SZ)公佈,公司於近日收到了哥斯達黎加衞生部簽發的注射用鹽酸萬古黴素500mg的上市許可。
鹽酸萬古黴素用於治療由耐甲氧西林(β-內酰胺)葡萄球菌敏感菌株引起的嚴重感染。它適用於青黴素過敏患者、不能接受或對其他藥物(包括青黴素或頭孢菌素)沒有反應的患者,以及萬古黴素敏感生物引起的對其他抗菌藥物有抵抗力的感染。對葡萄球菌性心內膜炎、以及葡萄球菌所致的其他感染包括敗血症、骨髓炎、下呼吸道感染、皮膚和皮膚組織感染等有效。
該上市許可的獲得,標誌着普利製藥具備了在哥斯達黎加銷售注射用鹽酸萬古黴素的資格,將對公司拓展哥斯達黎加市場帶來積極影響。同時,公司的注射用鹽酸萬古黴素其他市場的註冊工作正在持續推進中。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.